SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
KERYX BIOPHAMAEUTICALS INC
(NQSC:KERX Last Sale: 9 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQSC: (KERX : $9)
$551 million Market Cap at September 12, 2013
Employs 17.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
750 Lexington Avenue Research Report Earnings Snapshot - Last 11/06/18
20th Floor Fact Sheet
New York, NY 10022 Financial Statements
Phone: (212) 531-5965 Peer Comparison
Annual Reports

Michael P. Tarnok, Chmn., Ron Bentsur, CEO, James F. Oliviero, CFO
Applies data from the human genome for the systematic discovery of new drugs. The KinAce bioinformatics drug discovery platform enables the company to use this data to generate drug candidates targeting protein kinases. IPO at $10 July 27, 2000. Raised $46 million, selling 4.6 million shares, 24% of the outstanding. Lead Manager: Cruttenden Roth. Secondary sold 4.5 million shares at $18.40, raising $82.8 million, March 27, 2006. Received fast-track approval on Colorectal Cancer treatment, perifosine, April 5, 2010. Founded in 1998.
Historical Charts    Technical Analysis
No Historical Data available for KERX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common KERX $9 $ 0 $8.8 $9.1104 880,065 $2.2 $9.98 61,179
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $550,611

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex